InsiderSignal.AI

InsiderSignal.ai

ALXO - Alx Oncology Holdings Inc

Insider Purchase by Lettmann Jason (CEO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Lettmann Jason, serving as CEO at Alx Oncology Holdings Inc (ALXO), purchased 92,233 shares at $1.08 per share, for a total transaction value of $99,352.00. Following this transaction, Lettmann Jason now holds 305,121 shares of ALXO.

This purchase represents a 43.00% increase in Lettmann Jason's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, September 16, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, September 18, 2025, 2 days after the trade was made.

Alx Oncology Holdings Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lettmann Jason

CEO

Jason Lettmann is the Chief Executive Officer of ALX Oncology Holdings Inc. (ALXO) since September 6, 2023, and a member of its board of directors since April 2020, having previously served from March 2015 to May 2017.[[1]](https://fintool.com/app/research/companies/ALXO/people/jason-lettmann)[[2]](https://www.biocom.org/people/jason-lettmann/)[[5]](https://alxoncology.com/about-us/board-of-directors/) At 47 years old, he holds a B.A. in Psychology from the University of Iowa and an MBA from the University of Michigan Ross School of Business.[[1]](https://fintool.com/app/research/companies/ALXO/people/jason-lettmann) Lettmann brings extensive experience in venture capital and biotech operations, including roles as Partner at Morgenthaler Ventures (since June 2009), General Partner at Lightstone Ventures (March 2012–July 2023), and Vice President at Split Rock Partners (June 2006–June 2009).[[1]](https://fintool.com/app/research/companies/ALXO/people/jason-lettmann)[[2]](https://www.biocom.org/people/jason-lettmann/) He previously served as CEO of Promedior, Inc., leading it through its acquisition by Roche, and as a director at Ra Pharmaceuticals (acquired by UCB) and several private biotech companies.[[1]](https://fintool.com/app/research/companies/ALXO/people/jason-lettmann) As CEO of ALX Oncology, he is a Class I director with his term expiring in 2027, while the board maintains strong independent oversight.[[1]](https://fintool.com/app/research/companies/ALXO/people/jason-lettmann)

View full insider profile →

Trade Price

$1.08

Quantity

92,233

Total Value

$99,352.00

Shares Owned

305,121

Trade Date

Tuesday, September 16, 2025

159 days ago

SEC Filing Date

Thursday, September 18, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Alx Oncology Holdings Inc

Company Overview

No company information available
View news mentioning ALXO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/390820

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime